- Home
- IAS vs HRMY Comparison
IAS vs HRMY Comparison
Compare IAS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAS | HRMY |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IAS | HRMY |
|---|---|---|
| Price | $10.28 | $39.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $12.02 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.2M | 780.1K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.72 | ★ 50.44 |
| EPS | 0.28 | ★ 3.17 |
| Revenue | $590,666,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $14.98 | $20.68 |
| Revenue Next Year | $11.43 | $15.93 |
| P/E Ratio | $36.80 | ★ $12.57 |
| Revenue Growth | 15.51 | ★ 21.13 |
| 52 Week Low | $6.26 | $25.52 |
| 52 Week High | $11.43 | $40.93 |
Technical Indicators
Market Signals| Indicator | IAS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 81.37 |
| Support Level | $10.26 | $32.77 |
| Resistance Level | $10.29 | $36.20 |
| Average True Range (ATR) | 0.03 | 1.23 |
| MACD | -0.01 | 0.39 |
| Stochastic Oscillator | 81.25 | 92.81 |
Price Performance
Historical ComparisonAbout IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.